No Data
No Data
Subdued Growth No Barrier To Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Price
Hendy Pharmaceuticals: Semi-Annual Report 2024
Hendy Pharmaceuticals: 2024 Semi-Annual Report Summary
Hengdi Pharmaceutical (301211.SZ): The net income in the first half of the year was 68.496 million yuan, a year-on-year decrease of 39.40%.
Gelonghui, August 28th - Hengdi Pharmaceutical (301211.SZ) released its 2024 interim report, with half-year revenue of 0.242 billion yuan, a year-on-year decrease of 40.39%; net income attributable to shareholders of the listed company was 68.496 million yuan, a year-on-year decrease of 39.40%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 65.0419 million yuan, a year-on-year decrease of 40.87%; basic earnings per share was 0.24 yuan.
Biocause Heilen Pharmaceutical Gets Nod to Register Heart Failure Drug
Hengdi Pharmaceutical (301211.SZ): Milinong Injection has obtained the pharmaceutical registration certificate.
On August 14th, Gelunhui reported that Hendi Pharmaceutical (301211.SZ) announced that the company has recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA). The name of the drug is Milinong Injection. Milinong Injection is a positive inotropic drug and vasodilator. At the concentration that produces positive inotropic effect and vasodilator effect, Milinong Injection is a selective inhibitor of cAMP phosphodiesterase third peak isozyme in myocardium and vascular smooth muscle. It is suitable for the short-term intravenous treatment of patients with acute decompensated heart failure. The company's Milinong Injection obtained approval from NMPA.
No Data
No Data